You're more infectious if you have COVID-19 symptoms than if you're asymptomatic

Publicly released:
International
Photo by Brittany Colette on Unsplash
Photo by Brittany Colette on Unsplash

People with asymptomatic COVID-19 are less infectious than those who develop symptoms, according to an international systematic review. The researchers combined studies looking at how common asymptomatic infections are, and how frequently symptomatic or asymptomatic people spread the virus. They say research varies on how common it is for people to be persistently asymptomatic, with many who have no symptoms when they test positive going on to develop symptoms later. They conclude people with symptoms are more likely to infect others, and it appears transmission is higher in asymptomatic people who go on to develop symptoms than those who remain asymptomatic.

Media release

From: PLOS

Peer-reviewed                     Systematic review; Meta-analysis                      People

Asymptomatic SARS-CoV-2 infections responsible for spreading of COVID-19 less than symptomatic infections

Review of 130 different studies finds proportion of asymptomatic infection 50% or lower in most studies

Based on studies published through July 2021, most SARS-CoV-2 infections were not persistently asymptomatic, and asymptomatic infections were less infectious than symptomatic infections. These are the conclusions of an update of a systematic review and meta-analysis publishing May 26th in the open access journal PLOS Medicine by Diana Buitrago-Garcia of the University of Bern, Switzerland, and colleagues.

Debate about the level and risks of asymptomatic SARS-CoV-2 infections continues, with much ongoing research. Studies that assess people at just one time point can overestimate the proportion of true asymptomatic infections because those who go on to later develop symptoms are incorrectly classified as asymptomatic rather than presymptomatic. However, other studies can underestimate asymptomatic infections with research designs that are more likely to include symptomatic participants.

The new paper was an update of a living (as in, regularly updated) systematic review first published in April 2020, which includes additional, more recent studies through July 2021. 130 studies were included, with data on 28,426 people with SARS-CoV-2 across 42 countries, including 11,923 people defined as having asymptomatic infection. Because of extreme variability between included studies, the meta-analysis did not calculate a single estimate for asymptomatic infection rate, but it did estimate the inter-quartile range to be that 14–50% of infections were asymptomatic. Additionally, the researchers found that the secondary attack rate—a measure of the risk of transmission of SARS-CoV-2 — was about two-thirds lower from people without symptoms than from those with symptoms (risk ratio 0.32, 95%CI 0.16–0.64).

“If both the proportion and transmissibility of asymptomatic infection are relatively low, people with asymptomatic SARS-CoV-2 infection should account for a smaller proportion of overall transmission than presymptomatic individuals,” the authors say, while also pointing out that “when SARS-CoV-2 community transmission levels are high, physical distancing measures and mask-wearing need to be sustained to prevent transmission from close contact with people with asymptomatic and presymptomatic infection.”

Coauthor Nicola Low adds, “The true proportion of asymptomatic SARS-CoV-2 infection is still not known, and it would be misleading to rely on a single number because the 130 studies that we reviewed were so different. People with truly asymptomatic infection are, however, less infectious than those with symptomatic infection.”

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research PLOS, Web page The URL will go live after the embargo ends
Journal/
conference:
PLOS Medicine
Research:Paper
Organisation/s: University of Bern, Switzerland
Funder: This study was funded by the Swiss National Science Foundation http://www.snf.ch/en (NL: 320030_176233); the European Union Horizon 2020 research and innovation programme https://ec.europa.eu/programmes/horizon2020/en (NL: 101003688); the Swiss government excellence scholarship https://www.sbfi.admin.ch/ sbfi/en/home/education/scholarships-and-grants/ swiss-government-excellence-scholarships.html (DBG: 2019.0774) and the Swiss School of Public Health Global P3HS stipend https://ssphplus.ch/en/ (DBG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Media Contact/s
Contact details are only visible to registered journalists.